Cat. No.
MABL-3713
Application
therapeutic, FC
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
Vedolizumab (LDP-02)
From
Recombinant Antibody
Specificity
This antibody is specific for human α4β7 integrin and does not cross react with alpha(4)beta(1) and alpha(E)beta(7) integrins. This antibody does not bind majority of memory CD4(+) T lymphocytes (60%), neutrophils, and most monocytes. It binds to a subset (approximately 25%) of human peripheral blood memory CD4(+) T lymphocytes that include gut-homing interleukin 17 T-helper lymphocytes. It also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels
Alternative Names
Integrin α4β7; CD49D; ITGA4:ITGB7; Peyer patches-specific homing receptor LPAM-1; ITGA4; Integrin alpha-4; CD49 antigen-like family member D; Integrin alpha-IV; VLA-4 subunit alpha; ITGB7; Integrin beta-7; Gut homing receptor beta subunit; ACT-1; LDP02; MLN-02; MLN0002; MLN02; ENTYVIO
UniProt
P26010; P13612
Immunogen
This humanized antibody is derived from parental mouse antibody ACT-1 and was generated by grafting the CDRs of the mouse antibody onto human framework regions.
Application Notes
The binding characterization of this antibody for human alpha 4 beta 7 integrin was done using flow cytometry on Hut-78 cells (US7147851B1). In a double-blind, placebo-controlled trial this antibody was more effective than placebo for the induction of clinical and endoscopic remission in patients with active ulcerative colitis (PMID: 15958805). In a phase II clinical trial, it was reported that this antibody is well tolerated in patients with active Crohn's disease and therapy with this antibody had a dose- dependent beneficial effect on clinical remission (PMID: 18829392). This antibody exclusively binds alpha4 beta7 integrin and modulates inflammation in the gastrointestinal tract without inducing the systemic immunosuppression. This antibody binds memory CD4(+) T and B lymphocytes with sub nanomolar potency (EC(50) = 0.3-0.4 nM).
Antibody First Published
Feagan et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005 Jun 16;352(24):2499-507. PMID:15958805
Note on publication
This study reports the results of treatment with MLN02, a humanized antibody to the alpha4beta7 integrin, in patients with active ulcerative colitis.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
